Breaking News Instant updates and real-time market news.

AGIO

Agios Pharmaceuticals

$91.06

-0.23 (-0.25%)

, CELG

Celgene

$85.09

-0.26 (-0.30%)

20:07
07/22/18
07/22
20:07
07/22/18
20:07

Agios' Tibsovo approved earlier, launch should go well, says Piper Jaffray

Piper Jaffray analyst Tyler Van Buren notes that Agios (AGIO) announced the FDA approval of Tibsovo for relapsed/refractory acute myeloid leukemia, which represents the company's second approved drug product within the past year. The analyst points out that both Tibsovo and Idhifa, which was approved August 2017, cover approximately 20% of all AML patients who harbor IDHm mutations. Due to partner Celgene (CELG) and Agios' existing Idhifa launch efforts and the strong awareness of and similarity between both products, Van Buren expects the Tibsovo launch to be as good as - if not better - than the early Idhifa launch. Over time, he believes that Tibsovo can treat the majority of U.S; AML patients with IDH1 mutations and generate sales approaching $150M. The analyst reiterates an Overweight rating and $125 price target on Agios shares.

AGIO

Agios Pharmaceuticals

$91.06

-0.23 (-0.25%)

CELG

Celgene

$85.09

-0.26 (-0.30%)

  • 26

    Jul

  • 21

    Aug

AGIO Agios Pharmaceuticals
$91.06

-0.23 (-0.25%)

05/23/18
SBSH
05/23/18
INITIATION
Target $117
SBSH
Buy
Citi starts Agios with Buy rating, $117 price target
Citi analyst Mohit Bansal started Agios Pharmaceuticals with a Buy rating and $117 price target. Agios is a "unique" company with the potential to have multiple products on markets in next three years, Bansal tells investors in a research note. He believes the company has a "substantial opportunity" with its metabolic oncology and rare disease pipeline. The analyst has a "bull case" valuation of $170-$180 per share and takeover valuation of $180-$200 per share.
05/30/18
PIPR
05/30/18
INITIATION
Target $125
PIPR
Overweight
Agios Pharmaceuticals initiated with an Overweight at Piper Jaffray
Piper Jaffray analyst Tyler Van Buren started Agios Pharmaceuticals with an Overweight rating and $125 price target. The analyst believes both Idhifa and Tibsovo will experience commercial success while AG-348 for pyruvate kinase deficiency could represent a $750M-plus opportunity. He sees "no shortage of potential opportunities for future value creation."
06/04/18
JPMS
06/04/18
NO CHANGE
JPMS
Overweight
JPMorgan says Agios data reinforces additive benefit potential of ivosidenib
JPMorgan analyst Anupam Rama said updates from the phase 1b trial center on the ivosidenib combination arm includes an incremental increase in ORR and in-line CR rates with larger patient dataset, which reinforces his view of the potential for meaningful additive benefit from IDH inhibition on top of azacitidine. Rama added that he did not see any major incremental safety concerns in the data. Rama has an Overweight rating on Agios shares, which are down nearly 11% in morning trading.
06/04/18
PIPR
06/04/18
NO CHANGE
PIPR
Overweight
Agios' ivosidenib combo data support use in frontline AML, says Piper Jaffray
Piper Jaffray analyst Tyler Van Buren noted that the combo of ivosidenib plus Vidaza demonstrated "robust" clinical activity, including the rough doubling of ORR and CR rates compared to Vidaza monotherapy, and he believes the data shared at ASCO are supportive of the combination being used in the frontline AML setting. If these earlier trial results are replicated in the AGILE Phase 3 study, Van Buren sees a high probability of this combo being approved and used in the frontline AML setting, he tells investors. He maintains an Overweight rating on shares of Agios Pharmaceuticals, which are down 5% to $91.92 in afternoon trading.
CELG Celgene
$85.09

-0.26 (-0.30%)

07/10/18
PIPR
07/10/18
NO CHANGE
PIPR
Neutral
Celgene raised prices on both Revlimid and Pomalyst by 5%, says Piper Jaffray
Piper Jaffray analyst Christopher Raymond noted that Wolters Kluwer Health reports that Celgene increased its prices for Revlimid and Pomalyst by 5%, effective yesterday. The analyst, who pointed out that this is the first increase since October 2017 for both drugs, said the price hikes should provide some tailwind to Celgene's second half results. He maintains his Neutral rating on Celgene shares.
07/11/18
PIPR
07/11/18
NO CHANGE
Target $365
PIPR
Overweight
Biogen price target raised to $365 from $353 at Piper Jaffray
Piper Jaffray analyst Christopher Raymond raised his price target for Biogen (BIIB) to $365 saying a survey of 101 neurologists gives him increased confidence in the staying power of the company's multiple sclerosis franchise. Tecfidera market share "edged up slightly" during the quarter, and the survey shows signs of Roche's (RHHBY) Ocrevus "hitting a bit of a wall," Raymond tells investors in a research note. Further, the analyst continues to hear feedback that Celgene's (CELG) ozanimod "will be minimally differentiated." Despite increased signs of payer activism in the space, Biogen's MS franchise is well positioned for the near-to-intermediate term, Raymond contends. He raised his estimates for Tecfidera and keeps an Overweight rating on Biogen.
07/11/18
ADAM
07/11/18
NO CHANGE
Target $140
ADAM
Buy
Celgene's Buy rating backed at Canaccord following Phase 3 Impassion130 results
Canaccord analyst John Newman maintained a Buy rating and $140 price target on Celgene (CELG) after the company said that the Phase 3 Impassion130 study showed progression-free survival, or PFS, improvement for 1L metastatic or unresectable triple negative breast cancer with Abraxane plus Tecentriq (RHHBY) , which opens the door to Tencentriq in this indication. In a research note to investors, Newman says he expects continued upside from pipeline advances and diversification based on in-licensing, M&A and organic R&D and that, as there are currently no alternatives to chemotherapy, the combination of Abraxane plus Tecentriq should see widespread use if approved. He views the advances in TNBC "very positively" given the high unmet need for viable therapy.
07/12/18
PIPR
07/12/18
NO CHANGE
Target $95
PIPR
Neutral
PTAB decision on Gilenya positive for Celgene, says Piper Jaffray
Piper Jaffray analyst Christopher Raymond expects the market to react positively with respect to Celgene (CELG) shares, at least initially, following the Patent Trial and Appeal Board decision regarding ozanimod competitor Gilenya from Novartis (NVS). Yesterday, the PTAB issued a decision that upholds validity of Gilenya's dosing patent in response to inter partes review petitions from multiple generic filers, Raymond tells investors in a research note. While this decision will likely be appealed, it opens up the possibility for Gilenya intellectual property runway out to 2027, when the dosing patent expire, the analyst adds. Raymond believes that not having a generic S1P class at launch for ozanimod is positive for Celgene. However, without the removal of first dose monitoring, ozanimod is not likely to be differentiated enough to make a difference, the analyst says, citing physician feedback. He keeps a Neutral rating on Celgene with a $95 price target. The stock in early trading is up 2% to $84.92.

TODAY'S FREE FLY STORIES

WMT

Walmart

$97.89

-0.74 (-0.75%)

13:37
08/18/18
08/18
13:37
08/18/18
13:37
Periodicals
Walmart asks beauty suppliers to consider sourcing outside of China, Reuters say »

Walmart has asked some…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TCEHY

Tencent

$0.00

(0.00%)

13:26
08/18/18
08/18
13:26
08/18/18
13:26
Periodicals
Tencent-backed Qutoutiao files for U.S. IPO, Reuters reports »

Chinese content…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FB

Facebook

$173.78

-0.98 (-0.56%)

, AMZN

Amazon.com

$1,881.94

-5.56 (-0.29%)

13:10
08/18/18
08/18
13:10
08/18/18
13:10
Periodicals
Selloff in Chinese internet stocks may shake faith in FANG, Reuters says »

A steep downturn in…

FB

Facebook

$173.78

-0.98 (-0.56%)

AMZN

Amazon.com

$1,881.94

-5.56 (-0.29%)

NFLX

Netflix

$316.78

-5.51 (-1.71%)

GOOG

Alphabet

$1,199.79

-6.21 (-0.51%)

GOOGL

Alphabet Class A

$1,215.50

-8.05 (-0.66%)

TCEHY

Tencent

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Aug

  • 22

    Aug

  • 06

    Sep

  • 13

    Sep

  • 18

    Sep

  • 20

    Sep

  • 28

    Oct

VLKAY

Volkswagen

$0.00

(0.00%)

13:05
08/18/18
08/18
13:05
08/18/18
13:05
Periodicals
Volkswagen CEO was told about emissions software months before, Reuters reports »

Volkswagen CEO Herbert…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

WMT

Walmart

$97.89

-0.74 (-0.75%)

, TCEHY

Tencent

$0.00

(0.00%)

13:01
08/18/18
08/18
13:01
08/18/18
13:01
Hot Stocks
Walmart, Flipkart announce completion of investment »

Walmart (WMT) and…

WMT

Walmart

$97.89

-0.74 (-0.75%)

TCEHY

Tencent

$0.00

(0.00%)

MSFT

Microsoft

$107.58

-0.07 (-0.07%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 04

    Sep

  • 12

    Sep

BBOX

Black Box

$1.64

0.09 (5.81%)

12:57
08/18/18
08/18
12:57
08/18/18
12:57
Hot Stocks
Black Box announces sale agreement of Federal Government IT Services Business »

Black Box announced that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

KSS

Kohl's

$76.43

1.68 (2.25%)

12:52
08/18/18
08/18
12:52
08/18/18
12:52
Periodicals
Kohl's looking to break cycle, Barron's says »

Kohl's is set to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Aug

STT

State Street

$84.95

0.73 (0.87%)

12:47
08/18/18
08/18
12:47
08/18/18
12:47
Periodicals
State Street selloff looks overdone, Barron's says »

At the moment, State…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

WMT

Walmart

$97.89

-0.74 (-0.75%)

, AMZN

Amazon.com

$1,881.94

-5.56 (-0.29%)

12:42
08/18/18
08/18
12:42
08/18/18
12:42
Periodicals
May be time to sell Walmart, Barron's says »

In a follow-up story,…

WMT

Walmart

$97.89

-0.74 (-0.75%)

AMZN

Amazon.com

$1,881.94

-5.56 (-0.29%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Sep

VZ

Verizon

$54.79

0.51 (0.94%)

12:39
08/18/18
08/18
12:39
08/18/18
12:39
Periodicals
Verizon remains 'reasonably' priced, Barron's says »

In a follow-up story,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CF

CF Industries

$47.52

0.25 (0.53%)

, MOS

Mosaic

$29.64

(0.00%)

12:36
08/18/18
08/18
12:36
08/18/18
12:36
Periodicals
CF, Mosaic gains have just begun, Barron's says »

CF Industries (CF),…

CF

CF Industries

$47.52

0.25 (0.53%)

MOS

Mosaic

$29.64

(0.00%)

NTR

Nutrien

$55.95

0.94 (1.71%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 11

    Sep

  • 06

    Nov

ABBV

AbbVie

$98.79

0.6 (0.61%)

, LYB

LyondellBasell

$113.07

1.155 (1.03%)

12:25
08/18/18
08/18
12:25
08/18/18
12:25
Periodicals
StAbbVie, Starbucks among dividend standouts, Barron's says »

AbbVie (ABBV),…

ABBV

AbbVie

$98.79

0.6 (0.61%)

LYB

LyondellBasell

$113.07

1.155 (1.03%)

AVGO

Broadcom

$209.27

0.6 (0.29%)

RF

Regions Financial

$19.48

0.09 (0.46%)

SBUX

Starbucks

$53.58

0.53 (1.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Sep

  • 05

    Sep

  • 06

    Sep

  • 11

    Sep

  • 12

    Sep

  • 12

    Sep

BV

BrightView

$17.49

-0.06 (-0.34%)

12:21
08/18/18
08/18
12:21
08/18/18
12:21
Periodicals
Sunny outlook for BrightView, Barron's says »

BrightView's stock…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HOG

Harley-Davidson

$42.26

1.15 (2.80%)

, CSIQ

Canadian Solar

$13.12

0.02 (0.15%)

11:18
08/18/18
08/18
11:18
08/18/18
11:18
Hot Stocks
Week in review: How Trump's policies moved stocks »

Catch up on the top…

HOG

Harley-Davidson

$42.26

1.15 (2.80%)

CSIQ

Canadian Solar

$13.12

0.02 (0.15%)

FSLR

First Solar

$50.98

0.18 (0.35%)

JASO

JA Solar

$0.00

(0.00%)

SUNEQ

SunEdison

$0.00

(0.00%)

SPWR

SunPower

$6.65

0.06 (0.91%)

TSL

Trina Solar

$0.00

(0.00%)

YGE

Yingli Green Energy

$0.00

(0.00%)

PEP

PepsiCo

$114.98

0.7 (0.61%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    Oct

LYV

Live Nation

$48.15

-0.53 (-1.09%)

17:46
08/17/18
08/17
17:46
08/17/18
17:46
Hot Stocks
Live Nation CFO discloses sale of 40K shares of common stock »

Live Nation CFO Elizabeth…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

XLE

Energy Select Sector SPDR

$72.63

0.21 (0.29%)

, XLU

Utilities SPDR

$54.50

0.25 (0.46%)

17:40
08/17/18
08/17
17:40
08/17/18
17:40
General news
Week ending ETF Scorecard: Consumer Staples outperforms, Energy skids »

S&P500 SECTORS:…

XLE

Energy Select Sector SPDR

$72.63

0.21 (0.29%)

XLU

Utilities SPDR

$54.50

0.25 (0.46%)

IYR

DJ US Real Estate Index Fund

$83.16

0.765 (0.93%)

XLP

Consumer Staples Sector SPDR

$55.02

0.39 (0.71%)

XLY

Consumer Discretionary Sector SPDR

$112.51

0.11 (0.10%)

XLB

S&P Select Materials SPDR

$58.41

0.41 (0.71%)

XLF

Financial Select Sector

$28.16

0.055 (0.20%)

XLV

Health Care Select Sector SPDR

$91.12

0.33 (0.36%)

XLK

Technology Select Sector SPDR

$73.17

0.14 (0.19%)

XLI

Industrial Select Sector SPDR

$76.26

0.47 (0.62%)

GLD

SPDR Gold Trust

$112.12

1.01 (0.91%)

SLV

iShares Silver Trust

$13.93

0.16 (1.16%)

USO

United States Oil Fund

$13.70

0.065 (0.48%)

UNG

United States Natural Gas Fund

$24.18

0.295 (1.24%)

HYG

iShares iBoxx $ High Yield Corporate Bond

$86.03

0.08 (0.09%)

LQD

iShares iBoxx $ Investment Grade Corporate Bond

$115.97

0.11 (0.09%)

TLT

iShares 20+ Year Treasury Bond Fund

$120.99

0.16 (0.13%)

IEF

iShares 7-10 Year Treasury Bond ETF

$102.49

0.04 (0.04%)

SHY

iShares 1-3 Year Treasury Bond

$83.28

0.03 (0.04%)

IWD

iShares Russell 1000 Value

$126.16

0.6 (0.48%)

IWF

iShares Russell 1000 Growth

$150.80

0.27 (0.18%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GLD

SPDR Gold Trust

$112.12

1.01 (0.91%)

17:33
08/17/18
08/17
17:33
08/17/18
17:33
Hot Stocks
SPDR Gold Trust holdings fall to 772.24MT from 773.41MT »

This is the 5th…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GDOT

Green Dot

$85.04

0.37 (0.44%)

17:30
08/17/18
08/17
17:30
08/17/18
17:30
Hot Stocks
Green Dot exec Dent sells 7,754 common shares »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Sep

SMSI

Smith Micro

$2.49

-0.01 (-0.40%)

17:17
08/17/18
08/17
17:17
08/17/18
17:17
Syndicate
Breaking Syndicate news story on Smith Micro »

Smith Micro files to sell…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NDRA

ENDRA Life Sciences

$2.70

0.2 (8.00%)

17:14
08/17/18
08/17
17:14
08/17/18
17:14
Syndicate
Breaking Syndicate news story on ENDRA Life Sciences »

ENDRA Life Sciences files…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BA

Boeing

$346.44

0.55 (0.16%)

17:10
08/17/18
08/17
17:10
08/17/18
17:10
Hot Stocks
Boeing awarded $152.5M U.S. Navy contract »

Boeing is awarded a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BA

Boeing

$346.44

0.55 (0.16%)

17:09
08/17/18
08/17
17:09
08/17/18
17:09
Hot Stocks
Boeing awarded $217M Defense Department contract »

The Boeing Co has been…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

LLL

L3 Technologies

$210.37

0.56 (0.27%)

17:08
08/17/18
08/17
17:08
08/17/18
17:08
Hot Stocks
L3 Technologies awarded $240M Defense Department contract »

L-3 Communications was…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HSGX

Histogenics

$2.65

-0.05 (-1.85%)

17:06
08/17/18
08/17
17:06
08/17/18
17:06
Syndicate
Breaking Syndicate news story on Histogenics »

Histogenics files $75M…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PLD

Prologis

$67.45

1.79 (2.73%)

, DCT

DCT Industrial

$68.77

1.805 (2.70%)

16:58
08/17/18
08/17
16:58
08/17/18
16:58
Conference/Events
DCT Industrial to host special shareholder meeting »

Special Shareholder…

PLD

Prologis

$67.45

1.79 (2.73%)

DCT

DCT Industrial

$68.77

1.805 (2.70%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.